R&D channel feed

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

4 weeks ago

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

4 weeks ago

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

4 weeks ago
FDA+

GSK, Spero re­port Phase 3 win for UTI an­tibi­ot­ic; Sper­o's stock soars

4 weeks ago

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

4 weeks ago

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

4 weeks ago

Bound­less Bio changes plans for can­cer drug af­ter tox­i­c­i­ty is­sues

4 weeks ago
People

Gil­gamesh’s short-act­ing psy­che­del­ic drug shows rapid ef­fect in Phase 2 de­pres­sion study

4 weeks ago

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

4 weeks ago
People

Ku­ra spells out piv­otal AML tri­al win as it gears up to com­pete with Syn­dax

4 weeks ago

Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

4 weeks ago
Pharma

Volas­tra un­veils first hu­man da­ta of its sol­id tu­mor drug tar­get

4 weeks ago

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

5 weeks ago

Roche con­firms over­all sur­vival ben­e­fit for PI3K in­hibitor in breast can­cer

5 weeks ago
Pharma

Jazz out­lines full sur­vival da­ta for lung can­cer drug Zepzel­ca

5 weeks ago
Pharma

BioN­Tech in­vests £1B in grow­ing UK foot­print un­der ex­pand­ed pact with gov­ern­ment

5 weeks ago
Deals

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

5 weeks ago

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

5 weeks ago
Deals

How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion

5 weeks ago

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Last month
FDA+

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

Last month
Cell/Gene Tx

Tour­ma­line Bio's heart drug cuts in­flam­ma­tion as it seeks to com­pete with No­vo, CSL's as­sets 

Last month

Boehringer In­gel­heim’s late-stage da­ta for lung dis­ease can­di­date un­der­whelm some an­a­lysts

Last month

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

Last month
People
Cell/Gene Tx
First page Previous page 1234567 Next page Last page
A service from the Financial Times